Last reviewed · How we verify

Hairy cell leukemia patients with thrombocytopenia — Treatment Landscape & Competitive Intelligence

Hairy cell leukemia patients with thrombocytopenia (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hairy cell leukemia patients with thrombocytopenia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Nipent Pentostatin Pfizer Inc. Nucleoside Metabolic Inhibitor [EPC] Adenosine deaminase (ADA)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 1 drug in Hairy cell leukemia patients with thrombocytopenia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hairy cell leukemia patients with thrombocytopenia:

Cite this brief

Drug Landscape (2026). Hairy cell leukemia patients with thrombocytopenia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hairy-cell-leukemia-patients-with-thrombocytopenia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing